2021.01 – 2022.08 - Icahn School of Medicine at Mount Sinai - Lecturer
2017.01 – 2020.12 - Icahn School of Medicine at Mount Sinai - Postdoctoral Researcher
2013.07 – 2014.07 - Purdue University - Postdoctoral Researcher
2011.08 – 2013.07 - University of Hawaii - Postdoctoral Researcher
Research
Development of innovative tumor and other major disease target protein degraders based on PROTAC technology Development and application of novel E3 ubiquitin ligase ligands Synthesis and chemical biology research of GPCR small molecule agonists, inhibitors, and allosteric modulators with high bioactivity and selectivity
Discovery of Potent and Selective WDR5 PROTACs as Potential Therapeutic for Pancreatic Cancer, Yu, X.; Li, D.; Kottur, J.; Kim, H.S.; Herring, L.; Yu, Y.; Xie, L.; Hu, X.; Chen, X.; Cai, L.; Liu, J.; Aggarwal, A. K.; Wang, G. G.; Jin, J., 2023
Chemically Induced Degradation of Epigenetic Targets, Mabir, M.; Yu, X.; Kaniskan, H. U.; Jin, J., 2023
Dissecting and Targeting Noncanonical Functions of EZH2 in Multiple Myeloma via an EZH2 Degrader, Yu, X.; Wang, J.; Gong, W.; Ma, A.; Shen, Y.; Zhang, C.; Liu, X.; Cai, L.; Liu, J.; Wang, G. G.; Jin, J., 2023
Novel Allosteric Inhibitor-derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells, Yu, X.; Xu, J.; Cahuzac, K. M.; Xie, L.; Shen, Y.; Liu, J.; Parsons, R.; Jin, J., 2022
TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors, Liu, J.; Yu, X.; Chen, H.; Kaniskan, H. U.; Xie, L.; Chen, X.; Jin, J.; Wei, W., 2022
Targeting Triple-negative Breast Cancer by a Novel Proteolysis Targeting Chimera (PROTAC) Degrader of Enhancer of Zeste Homolog 2 (EZH2), Dale, B.; Anderson, C.; Park, K. S.; Kaniskan, H. U.; Ma, A.; Shen, Y.; Zhang, C.; Xie, L.; Chen, X.; Yu, X.; Jin, J., 2022
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras, Yu, X.; Cheng, M.; Lu, K.; Shen, Y.; Zhong, Y.; Liu, J.; Xiong, Y.; Jin, J., 2022
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic, Li, D.; Yu, X.; Kottur, J.; Gong, W.; Zhang, Z.; Storey, A. J.; Tsai, Y.-H.; Uryu, H.; Shen, Y.; Byrum, S. D.; Edmondson, R. D.; Mackintosh, S. G.; Cai, L.; Liu, Z.; Aggarwal, A. K.; Tackett, A. J.; Liu, J.; Jin, J.; Wang, G. G., 2022
Discovery of Potent, Selective and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-activity Relationship Studies, Yu, X.; Xu, J.; Shen, Y.; Cahuzac, K. M.; Park, K. S.; Dale, B.; Liu, J.; Parsons, R.; Jin, J., 2022
EZH2 non-canonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis, Wang, J.; Yu, X.; Gong, W.; Liu, X.; Park, K. S.; Ma, A.; Tsai, Y.-H.; Shen, Y.; Onikubo, T.; Pi, W.-C.; Allison, D. F.; Liu, J.; Chen, W.-Y.; Cai, L.; Roeder, R. G.; Jin, J.; Wang, G. G., 2022
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models, Yu, X.; Li, D.; Kottur, J.; Shen, Y.; Kim, H.S.; Park, K. S.; Tsai, Y.-H.; Gong, W.; Wang, J.; Suzuki, K.; Parker, J.; Herring, L.; Kaniskan, H. U.; Cai, L.; Jain, R.; Liu, J.; Aggarwal, A. K.; Wang, G. G.; Jin, J., 2021
Design, Synthesis and Evaluation of Potent, Selective and Bioavailable AKT Kinase Degraders, Yu, X.; Xu, J.; Xie, L.; Wang, L.; Shen, Y.; Cahuzac, K. M.; Chen, X.; Liu, J.; Parsons, R.; Jin, J., 2021
AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B, Xu, J.; Yu, X.; Martin, T. C.; Bansal, A.; Cheung, K.; Lubin, A.; Stratikopoulos, E.; Cahuzac, K. M.; Wang, L.; Xie, L.; Zhou, R.; Shen, Y.; Wu, X.; Shen, Y.; Qiao, R.; Poulikakos, P.; Chen, X.; Liu, J.; Jin, J.; Parsons, R., 2021
Design, Synthesis and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68), Yu, X.; Huang, X. P.; Kenakin, T. P.; Slocum, S. T.; Chen, X.; Martini, M. L.; Liu, J.; Jin, J., 2019
Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors, Yu, X.; Zhang, M.; Annamalai, T.; Bansod, P.; Narula, G.; Tse-Dinh Y.-C.; Sun, D., 2017
Structure-based Design of Potent HIV-1 Protease inhibitors with Modified P1-Biphenyl Ligands: Synthesis, Biological Evaluation, and Enzyme-inhibitor X-ray Structural studies, Ghosh, A. K.; Yu, X.; Osswald, H. L.; Agniswamy, J.; Wang, Y. F.; Amano, M.; Weber, I. T.; Mitsuya, H., 2015
Macrocyclic Drugs and Synthetic Methodologies toward Macrocycles, Yu, X.; Sun, D., 2013
Synthesis of 2-arylindole derivatives and evaluation as nitric oxide synthase and NFkB inhibitors, Yu, X.; Park, E. -J.; Kondratyuk, T. P.; Pezzuto, J. M.; Sun, D., 2012
Efficient Synthesis of 9-Tosylaminofluorene Derivatives by Boron Trifluoride Etherate-Catalyzed Aza-Friedel-Crafts Reaction of in situ Generated N-Tosylbenzaldimines, Yu, X.; Lu, X., 2011
Cationic Palladium Complex-Catalyzed Diastereoselective Tandem Annulation of 2-Iminoarylboronic Acids with Substituted Alkynes: Enantioselective Synthesis of Aminoindene Derivatives by Double Asymmetric Induction, Yu, X.; Lu, X., 2011
Facile Cu(OTf)2-catalyzed preparation of 9-Tosylaminofluorene derivatives from o-arylated N-Tosylbenzaldimines, Yu, X.; Lu, X., 2011
Cationic Palladium-Catalyzed [5+2] Annulation of 2-Acylmethoxyarylboronic Acids and Allenoates: Synthesis of 1-Benzoxepine Derivatives, Yu, X.; Lu, X., 2011
Cationic Palladium Complex Catalyzed Diastereo- and Enantioselective Tandem Annulation of 2-Formylarylboronic Acids with Allenoates, Yu, X.; Lu, X., 2009
